Abbott has issued a news release in which it provides sales figures for its Xience family of drug-eluting coronary stents (XIENCE V®, XIENCE PRIME™ and XIENCE nano™) which, according to the company, confirm the company’s position as market leader in this field. In the fourth quarter of 2011, the XIENCE family generated worldwide sales of nearly $400 million, supported by record sales in the United States and continued strong performance in Japan, China and other key international markets. According to Abbott, the Worldwide market share for the XIENCE family is nearly 40 percent – solidifying its number one position.
Coronary artery disease occurs when the arteries that supply blood to the heart become narrowed or blocked. Approximately 17 million people worldwide die each year from coronary artery disease, making it the number one cause of death around the world. Drug eluting stents such as XIENCE work by propping open the narrowed vessel to restore blood flow to the heart, and are considered to be the standard of care for the treatment of coronary artery disease.
Abbott engineers and scientists designed each component of the XIENCE V stent to improve on the safety and efficacy of previous generations of drug eluting stents – including the platform, the delivery system, the drug that is used, the concentration of the drug and the elution rate. Now, several years after its initial introduction, XIENCE V continues to show significant benefits for patients.
XIENCE is supported by the strong safety and efficacy results from Abbott’s SPIRIT family of clinical trials, which includes more than 10 studies and long-term results beyond five years. All told, the XIENCE family of stents has been studied in more than 100 clinical trials in more than 44,000 patients worldwide.
Building on XIENCE V’s success, Abbott has advanced its XIENCE platform with new products, such as XIENCE PRIME, a next-generation drug eluting stent that is offered in longer lengths to treat longer lesions, and XIENCE nano, a stent that has been specially designed to treat smaller vessels. The company continues to improve its offerings and has additional products in development, including a next-generation drug-eluting stent that incorporates an advanced balloon catheter for enhanced performance.
Interestingly the company refers to its Absorb bioresorbable vascular scaffold as being “in development”, when it’s actually CE marked and being implanted in Europeans right now. Absorb is designed to treat a patient’s blocked coronary artery to restore blood flow and then dissolve over time, much like dissolvable sutures.